The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide

Authors: Kallinich, T.; Hoffman, H. M.; Roth, J.; Keitzer, R.

Source: Scandinavian Journal of Rheumatology, Volume 34, Number 3, June 2005 , pp. 246-249(4)

Buy & download fulltext article:

Price: $34.29 plus tax (Refund Policy)

Abstract:

Chronic, infantile, neurological, cutaneous, and articular (CINCA) syndrome, also known as neonatal-onset multisystem inflammatory disease (NOMID), is a rare autosomal dominant inherited disease. It is characterized by a persistent rash with onset during the neonatal period, neurological and ocular manifestations, and articular involvement with abnormal ossification. Mutations within the CIAS1 gene are found in up to 60% of CINCA cases, but the exact underlying pathogenetic mechanisms causing this disorder are still unclear. Although the interleukin-1 (IL-1) receptor antagonist anakinra (rHuIL-1Ra) has recently been reported to be effective, no formal recommended treatment protocols exist thus far. Herein, we describe a 17-year-old girl with CINCA for whom numerous medication trials had been unsuccessful. After the introduction of thalidomide, the symptoms of arthropathy improved dramatically even months after the medication was discontinued by the patient. We propose that thalidomide can be beneficial in select patients with CINCA syndrome.

Document Type: Research article

DOI: http://dx.doi.org/10.1080/03009740410010236

Affiliations: 1: Division of Pediatric Allergy and Immunology, University of California at San Diego, USA

Publication date: 2005-06-01

More about this publication?